American Society for Microbiology

ASM CE Portal

Your source of Continuing Education for the American Society for Microbiology

Featured Activities

The goal of this session is to review the currently available commercial assays for multiplex detection of respiratory viruses.  Available assays will be reviewed, including performance and workflow data.  Further, advantages and disadvantages of using molecular techniques for the routine diagnosis of respiratory viral infections will be discussed.

Objectives: Upon completion of this webcast, participants should be able to:

  1. List at least two molecular platforms for the multiplex detection of respiratory viruses.
  2. Recall two advantages of detecting respiratory viruses by molecular testing.
  3. Cite one disadvantage of using molecular testing to diagnose respiratory viral infections.

Intended Audience: Laboratory medical or administrative director, laboratory manager, section or department head, pathologist, doctoral scientist or technologist.

Education Level - Intermediate.

\P.A.C.E.® 273-606-14.

Melissa B. Miller, Ph.D., D(ABMM)
Associate Professor, Pathology and Laboratory Medicine
UNC School of Medicine
Director, Clinical Molecular Microbiology Laboratory
Associate Director, Clinical Microbiology-Immunology Laboratory
UNC Health Care
Chapel Hill, NC


Method verification is an integral component of good laboratory practice.  This session will focus on the CLIA-requirements for verification of FDA-approved and non-FDA approved/laboratory developed tests.  Specifically, information and examples on methods for verification of highly multiplexed molecular tests will be discussed.

Upon completion of this activity, participants should be able to:

  • Define method verification, according to the Clinical Laboratory Improvement Amendments (CLIA).
  • Describe the performance characteristics that must be verified prior to the implementation of a FDA-approved test.
  • Describe the performance characteristics that must be established prior to the implementation of a laboratory developed test, or modified FDA-approved test.

Intended Audience: Laboratory medical or administrative director, laboratory manager, section or department head, pathologist, doctoral scientist or technologist.

Education Level - Intermediate.
P.A.C.E.® 273-605-14

Matthew Binnicker, Ph.D., D(ABMM)
Director, Clinical Virology
Associate Professor of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, MN

Appropriate design and workflow are major considerations for any molecular diagnostic laboratory. Historically, the physical plan of a molecular laboratory centered firmly on preventing amplicon contamination and necessitated distinct and separate work spaces or individual rooms for sample processing, reagent preparation, nucleic acid extraction, and detection and analysis of amplified targets.  With the evolution of molecular technology over the years, the more traditional molecular laboratory blueprint is now giving way to different designs with more adaptable physical features.

Objectives: Following this session, the participants should be able to: 

  1. Discuss the design and workflow of a molecular diagnostic laboratory.
  2. Define space and resource options and provide insight into the physical location of the molecular laboratory based on choice of technology and test menu.
  3. Describe the selection and implementation of good laboratory practices in the molecular laboratory.

Intended Audience: Laboratory medical or administrative director, laboratory manager, section or department head, pathologist, doctoral scientist or technologist.

Education Level - Intermediate.

Richard L. Hodinka, Ph.D. , F(AAM)
Professor, Pathology & Laboratory Medicine
Perelman Schoolof Medicine at the University of Pennsylvania
Director, Clinical Virology Laboratory
Children's Hospital of Philadelphia

2013 ICAAC Online

ICAAC is the world’s premier conference on infectious diseases and antimicrobial agents. ICAAC showcases the latest breaking science and lectures from top researchers from around the globe. With nearly 100 countries represented, and more than half of the attendees traveling from outside of the United States, ICAAC provides a unique global networking and educational opportunity. The ICAAC Program Committee designed a program of the highest quality to facilitate the exchange of new information among healthcare professionals, particularly physicians, clinical microbiologists, researchers, pharmacists and trainees specializing in infectious diseases.

Please Click Here for more information.

Participation in the ICAAC 2013 should allow attendees to:

  • Investigate the pathogenesis and epidemiology of old and new microbes;
  • Utilize new data from the research of basic microbiological sciences related to human disease to improve their clinical practice and patient outcomes;
  • Evaluate the spread of infectious diseases throughout the world;
  • Review state-of-the-art developments in the field, including timely reviews of recent advances in clinical care and research and original reports of clinical, translational, and basic research;
  • Identify the most recent trends in health care management;
  • Incorporate the knowledge gained to assist with bridging any gaps among the fields of infectious diseases clinical practice, clinical research, epidemiological and health services research, translational research, and basic research;
  • Recognize and better understand recent new antimicrobial agents;
  • Understand and discuss updates on clinical diagnoses, preventative modalities and therapeutics;
  • Analyze the developing resistance of pathogens to diverse therapeutics; and
  • Engage in networking and collaboration among clinicians and investigators to facilitate advances in the prevention, diagnosis, and treatment of infectious diseases.
  • The ICAAC 2013 is designed to meet the needs of health care professionals, particularly physicians, clinical microbiologists, researchers, and pharmacists, specializing in infectious diseases. Current trends will be covered regarding:

  • Antimicrobial Resistance
  • Clinical Trials
  • Community-Acquired Infections
  • Epidemiology
  • HIV/AIDS and other Retroviruses
  • Laboratory Diagnostics
  • Microbial Pathogenesis
  • Mycology
  • Nosocomial Infections
  • Parasitology
  • Pharmacology
  • Susceptibility Studies
  • Vaccines and Immunology
  • Virology
  • Session Type
    Contact Hours or AMA PRA Category 1 Credits™ per session
    Keynote Session
    1
    Poster Summary Session and Literature Review Session
    2
    Interactive Symposium and Symposium
    2
    Slide Sessions
    2.5
    Meet-the-Experts
    1.25
    ICAAC Lecture and Special Address
    1

    Molecular Diagnosis of Infectious Diseases Course

    This 12-part course provides an introduction to molecular biology and an explanation of molecular diagnostic methods as they are used and encountered in the clinical microbiology laboratory. Participants will learn the basic nucleic acid chemistries and molecular amplification technologies and will gain knowledge of different topics related to molecular diagnostic testing. Specifically, the course will address issues related to starting a molecular diagnostic laboratory; selecting reagents and instruments for nucleic acid isolation, amplification and detection; developing and/or implementing molecular assays; validating and verifying assay performance; performing quality control; and applying molecular tests to the detection of various microbial pathogens of clinical importance. The course will end by highlighting the many technological advances in the field.

    To purchase, please click here.

    Impact of New Microbiology Technology on Patient Outcomes

    As diagnostic microbiology laboratories evolve from profit to cost centers in the era of declining reimbursements, the clinical microbiologist will need a better understanding of how technology can impact on the quality of patient care. In this course, we will explore the latest advances in technology for microbiology, some of the issues surrounding these methods, and the overall impact of these newer tests on patient care and health outcomes.

    Click Here for more info.

    American Society For Microbiology © 2015.